Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$16.02
+$0.05 · +0.31%
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Latest quote
$16.02
+$0.05 · +0.31%
Regular session · ET · Market data may be delayed.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Day range
Current $16.02
52-week range
Current $16.02
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
73
Undervalued
Sentiment
72
Bullish
Risk
52
Elevated Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Day range
Current $16.02
52-week range
Current $16.02
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$23.50
46.69% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR122.64M0.12%102.88B USD0.06%$137.31+0.17%
First Trust NYSE Arca Biotechnology Index FundFBT102.47M3.56%2.87B USD0.55%$260.19-1.25%
Vanguard Morningstar Total Stock Market ETFVTI74.25M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM54.41M0.07%77.7B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap ETFVB53.61M0.03%185.3B USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Growth ETFVBK30.72M0.07%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF27.14M0.03%95.4B USD0.05%$233.13-0.15%
Invesco S&P SmallCap Momentum ETFXSMO21.77M0.76%2.87B USD0.35%$81.29-0.74%iShares Core S&P Small-Cap ETFIJRFirst Trust NYSE Arca Biotechnology Index FundFBTVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFInvesco S&P SmallCap Momentum ETFXSMOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
